Phase I Trial of Tanibirumab in Advanced or Metastatic Cancer

Inclusion Criteria:

* Age \> 20 years
* Signed informed consent
* Histologically documented, incurable, locally advanced or metastatic cancers that have failed to respond to at least one prior regimen or for which there is no standard therapy.
* Disease that is measurable or evaluable by RECIST 1.1 criteria (for Solid Tumors)
* ECOG performance status 0-2
* Documented negative pregnancy test for women of childbearing potential and use of an effective means of contraception for both men and women while enrolled in the study
* Granulocyte count ≥ 1,500/㎣, platelet count ≥ 100,000/㎣, and hemoglobin ≥ 9 g/dL
* Serum bilirubin ≤ 1.5 x upper limit of normal (ULN)(≤ 3 x ULN if liver metastatic cancer)
* Alkline phosphatase, AST and ALT ≤ 2.5 x ULN (≤ 5 x ULN if liver metastatic cancer)
* Serum creatinine ≤ 1.5 mg/dL
* INR (international normalized ratio) ≤ 1.3, and aPTT (activated partial thromboplastin time) ≤ 1.5 x ULN
* Subject had to have a projected life expectancy of at least 3 months
* Bazetts correction QTc \< 450 msec in ECG at Screening

Exclusion Criteria:

* Less than 4 weeks since last chemotherapy (including biologic unless previous Avastin treatment, experimental, and hormonal therapy), radiation therapy, or major surgical procedure
* All incisions from any procedure must be fully healed and sutures removed prior to infusion on Day 1
* Pleural effusions, ascites, or leptomeningeal disease as the only manifestation of the current malignancy
* Subjects that have hypertension that is remained uncontrolled, despite drug regimen.
* Subjects with grade III or IV hemorrhage/bleeding and who have experienced pulmonary hemorrhage/hemoptysis (exceed size of 2.5 mL of erythrocyte) or who have experienced grade III/IV hemorrhage/bleeding.
* The presence of gastrointestinal perforation
* The presence of tracheoesophageal fistula or grade Ⅳ fistula
* Subjects with grade Ⅳ proteinuria (nephritic syndrome)
* The presence of arterial thromboembolic events
* Subjects who have history of life threatening (grade Ⅳ) pulmonary embolism
* Subjects with a known hypersensitivity to CHO cell product or other recombined human or humanized antibody
* Subjects with mental illness
* Subjects with a known hypersensitivity to any of the ingredients/substrates in investigational product of this study
* Subjects who given any investigational drug within longer period between 30 days and 5 times of half life before participation in this study
* Active infection requiring IV antibiotics
* Active autoimmune disease that is not controlled by drugs
* Clinically important history of liver disease, including viral or other active hepatitis, current alcohol abuse, or cirrhosis
* Known human immunodeficiency virus (HIV) infection
* Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the subjects at high risk from treatment complications
* Significant traumatic injury within 3 weeks of Day 1
* Inability to comply with study and follow-up procedures